Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified into 3 categories according to their severity as mild AEs (did not interfere with participant's usual function), moderate AEs (interfered to some extent with participant's usual function) and severe AEs (interfered significantly with participant's usual function).

Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

Population: SAS included all participants enrolled in this study who were part of a prior qualifying study, and who received at least one dose of open-label study medication in A3921092. Safety analysis included cumulative data for main and sub-study as pre-specified in protocol.

Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes,neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin \[total, direct, indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids (cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy (urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Laboratory abnormality: determined by investigator per pre-defined criteria.

Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

Population: SAS included all participants enrolled in this study who were part of prior qualifying study, and who received at least 1 dose of open-label study medication in A3921092. Safety analysis include cumulative data for main and sub-study as pre-specified in protocol.Overall number of participants analyzed=participants evaluable for this measure.

Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin\[total,direct,indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids(cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine-pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy(urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Clinically significant change: determined by investigator per pre-defined criteria.

Time frame: Date of first dose of study medication (Baseline) up to 48 months (36 months of main study and 12 months of sub-study)

Population: SAS included all participants enrolled in this study who were part of a prior qualifying study, and who received at least one dose of open-label study medication in A3921092. Safety analysis included cumulative data for main and sub-study as pre-specified in protocol.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 48 months that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

Population: SAS included all participants enrolled in this study who were part of a prior qualifying study, and who received at least one dose of open-label study medication in A3921092. Safety analysis included cumulative data for main and sub-study as pre-specified in protocol.

HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score ranged from 0 (least difficulty) to 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame: Sub-study: Baseline (Day 1), Month 6

Population: FAS of sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in millimeter (mm), swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), short form-36 questionnaire (SF-36) physical component summary (norm-based domain scores were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

Time frame: Sub-study: Baseline (Day 1), Month 6

Population: FAS of sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 centimeter (cm) with higher score represented more severe ankylosing spondylitis disease activity.

Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 with presence of spondylitis at screening and baseline BASDAI Score\>0 cm. Number analyzed =participants evaluable for this outcome measure at specified time points.

BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 cm with higher score represented more severe ankylosing spondylitis disease activity.

Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with presence of spondylitis at screening and baseline BASDAI score \>=4 cm. Number analyzed =participants evaluable for this outcome measure at specified time points.

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis severity score for a participant was 0-60. Higher score indicated greater severity.

Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline DSS \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this outcome measure.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this outcome measure.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30 and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: FAS population for main study included all enrolled participants who were part of prior qualifying study, and who received at least 1 dose of tofacitinib in A3921092. Number analyzed=participants evaluable for this outcome measure at specified time points.

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline LEI \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

The PGA-PsO was a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline PGA-PsO score \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains were aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores were used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represented better physical health status.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; & d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

Population: FAS of main study included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092. Number analyzed =participants evaluable for this outcome measure at specified time points.

The SPARCC enthesitis index identifies the presence or absence of tenderness at 16 enthesial sites, including (right and left): medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. On examination, tenderness was recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline SPARCC enthesitis index \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

Participants with 20% improvement from baseline in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: Patient's global assessment of arthritis (PtGA), Physician's global assessment of arthritis (PhyGA), participant's assessment of arthritis pain, HAQ-DI and C-reactive protein (CRP) in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: FAS population for main study included all enrolled participants who were part of prior qualifying study, and who received at least 1 dose of tofacitinib in A3921092. Number analyzed=participants evaluable for this outcome measure at specified time points.

Participants with 50% improvement from baseline in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: FAS population for main study included all enrolled participants who were part of prior qualifying study, and who received at least 1 dose of tofacitinib in A3921092. Number analyzed=participants evaluable for this outcome measure at specified time points.

Participants with 70% improvement from baseline in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: FAS population for main study included all enrolled participants who were part of prior qualifying study, and who received at least 1 dose of tofacitinib in A3921092. Number analyzed=participants evaluable for this outcome measure at specified time points.

PsARC is comprised of 4 clinical improvement criteria: greater than or equal to (\>=) 20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: FAS population for main study included all enrolled participants who were part of prior qualifying study, and who received at least 1 dose of tofacitinib in A3921092. Number analyzed=participants evaluable for this outcome measure at specified time points.

PASI: combined assessment of lesion severity and body area affected into single score; range =0 (no disease) -72 (maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0 (0%) - 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1 =slight, 2 =moderate, 3 =marked, 4 =very marked. Final PASI =sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.

Time frame: Main study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline BSA \>=3% and baseline PASI score \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of clinical sign components for erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) and severity estimated by clinical signs components for erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Time frame: Main study: Baseline(Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline BSA\>=3% and baseline PASI Score \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) & severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Time frame: Main study: Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Population: Analysis population included all enrolled participants who were part of a prior qualifying study, and who received at least one dose of tofacitinib in A3921092 and with baseline BSA\>=3% and baseline PASI score \>0. Number analyzed =participants evaluable for this outcome measure at specified time points.

The test for CRP was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline DSS \>0. Here, Number analyzed signifies those participants who were evaluable for this outcome measure at specified time points.

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this measure.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this measure.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard verticle 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \[washed out\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

HAQ-DI assessed the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least 1 dose of (tofacitinib, MTX or placebo).

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) and with baseline Leeds enthesitis index \>0. Here, Number analyzed signifies those participants who were evaluable for this outcome measure at specified time points.

Participants assessed the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. Higher score indicated more severe pain.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participant's response were recorded using a 0 - 100 mm VAS where 0 =not affected at all and 100 =extremely affected. Higher score indicated worse condition due to PSA.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and independent of the PtGA and Patient Assessment of Arthritis Pain. The investigator's response was recorded using a 100 mm VAS where 0 =PSA not active at all and 100 =PSA extremely active. Higher score indicated more PSA.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The PGA-PsO is a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

Time frame: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline PGA-PsO score\>0.

PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in mm, swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), SF-36 physical component summary (norm-based domain score were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and CRP in mg/L. PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least 1 dose of (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting & carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence & extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, & mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; & d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represented better vitality.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Joints were assessed for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Sixty-six (66) joints were assessed for swelling. The 66 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

68 joints were assessed to determine joints that are considered tender or painful. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints). The 68 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame: Sub-study: Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline LEI =0. Here, Number analyzed signifies those participants who were evaluable for this outcome measure at specified time points.

PsARC was comprised of 4 clinical improvement criteria: \>=20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

Time frame: Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

Time frame: Sub-study: Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline DSS \>0.

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame: Sub-study: Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline LEI \>0.

A psoriatic arthritis participant was considered with minimal disease activity if participant had \>= 5 of 7 criteria: 1) tender/painful joint count less than or equals to (\<=) 1; (2) swollen joint count \<=1; (3) BSA \<=3%; (4) Patient Assessment of Arthritis Pain (VAS) \<=15 mm; (5) PtGA (VAS) \<=20 mm; (6) HAQ-DI score \<=0.5; (7) tender entheseal points (using LEI) \<=1.

Time frame: Sub-study: Months 1, 3, 6, 9 and 12

Population: FAS for sub-study included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo).

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage (Head and neck = 10 handprints \[1 handprint =10%\], upper extremities = 20 handprints \[1 handprint =5%\], Trunk (including axillae and groin) = 30 handprints \[1 handprint =3.33%\], lower extremities (including buttocks) = 40 handprints \[1 handprint =2.5%\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

Population: Analysis population included all participants who were randomized to the sub-study and received at least one dose of the sub-study drug (tofacitinib, MTX or placebo) with baseline BSA \>0%. Here, Number analyzed signifies those participants who were evaluable for this outcome measure at specified time points.